General Electric’s Standard BioTools LAB Stock Holding History

General Electric’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-154,814	Closed	-$2.7M	–	217
2013 Q2	$2.7M	Buy	+154,814	New	+$2.72M	0.01%	172

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General Electric's LAB Position: Q3 2013 in Review

General Electric sold out of Standard BioTools (LAB) in Q3 2013, closing a stake of 154,814 shares — an estimated $2.7M sold.

General Electric first reported a position in LAB in Q2 2013 and held it in 1 quarter. The position peaked at $2.7M in Q2 2013. 89 funds tracked by Wall St. Rank hold LAB as of Q3 2013.

General Electric reported no remaining Standard BioTools position as of Q3 2013 after selling out during the quarter.
General Electric sold 154,814 Standard BioTools shares in Q3 2013, an estimated $2.7M.
General Electric first reported a position in Standard BioTools in Q2 2013 and held it in 1 quarter.
General Electric's Standard BioTools position peaked at $2.7M in Q2 2013.
89 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2013.

Based on General Electric's 13F filing for Q3 2013, filed 13 Nov 2013.